FindTrial
Sign In

The accuracy and safety of Reganosen in the measurement of flow reserve fraction (FFR) compared with adenosine

The accuracy and safety of Reganosen in the measurement of flow reserve fraction (FFR) compared with adenosine

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087342
Enrollment
Unknown
Registered
2024-07-25
Start date
2024-08-02
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary atherosclerotic heart disease

Interventions

Gold Standard:measurement of flow reserve fraction (FFR) with adenosine
Index test:measurement of flow reserve fraction (FFR) with Reganosen

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-75 years; (2) coronary angiography showed moderate to severe lesions (visual method: 50-90% diameter stenosis ) ; (3) be able to understand and follow the test procedure and agree to participate in the test and sign the written informed consent;

Exclusion criteria

Exclusion criteria: (1) acute myocardial infarction within 1 week; (2) severe allergic to adenosine, raganosen; (3) Second Degree or greater atrioventricular block and Bundle branch block; (4) severe pulmonary dysfunction or asthma attack; (5) Systolic blood pressure < 90mmHg or Hemodynamics instability; (6) patients with severe congestive heart failure;

Design outcomes

Primary

MeasureTime frame
fractional flow reserve;Consistency;—

Secondary

MeasureTime frame
Adverse reaction indicators;—

Countries

China

Contacts

Public ContactZhang Mingduo

Beijing Anzhen Hospital, Capital Medical University

wodexuexi@126.com+86 138 1120 2327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026